All In Biotech

Drug Trial Radar · NCT06979505

GV101 in Healthy Obese Participants

Dose-ranging Double-blind, Placebo-controlled Phase 2 Trial of GV101 for Weight Loss in Healthy Obese Participants

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Jun 30, 2025

Primary completion

Jan 28, 2026

Study completion Jan 28, 2026

Sponsor

Sponsor type
Industry
First posted
May 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.

Conditions

  • Weight Management

Interventions

  • GV101Drug

    GV101 suspension

  • GV101 placeboDrug

    GV101 placebo suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change in body weight from baseline at Week 16 in each treated group as compared with placeboTime frame: 16 weeks

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Lakeview Clinical Research, LLC

    Guntersville, Alabama

  • Arizona Clinical Trials

    Tucson, Arizona

  • Catalina Research Institute, LLC

    Montclair, California

  • Encompass Clinical Research

    Spring Valley, California

  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)

    Louisville, Kentucky

  • Tandem Clinical Research

    Marrero, Louisiana

  • Study Metrix Research

    City of Saint Peters, Missouri

  • Kansas City Research Institute

    Kansas City, Missouri

  • Mercury Street Medical

    Butte, Montana

  • Hassman Research Institute

    Berlin, New Jersey

  • Coastal Research Institute, LLC

    Fayetteville, North Carolina

  • Lillestol Research, LLC

    Fargo, North Dakota

  • Velocity Clinical Research - Cleveland

    Cleveland, Ohio

  • Velocity Clinical Research - Dallas

    Dallas, Texas

  • Advanced Research Institute - Ogden

    Ogden, Utah

  • Chrysalis Clinical Research

    St. George, Utah

  • Hadassah Medical Center Ein Karem

    Jerusalem, Israel, Israel

  • Hasharon Hospital

    Petah Tikva, Israel, Israel

  • Rabin Medical Center, Beilinson Hospital

    Petah Tikva, Israel, Israel

  • Sheba Medical Center

    Tel HaShomer, Israel, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.